ClinicalTrials.gg
RecruitingNCT07216157NoSealUpdated Oct 14, 2025

NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery

An interventional study of Standard multilayer closure without sealant and Fibrin sealant application in CerebroSpinal Fluid (CSF) Leak, sponsored by Maria Sklodowska-Curie National Research Institute of Oncology. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by Maria Sklodowska-Curie National Research Institute of Oncology · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Postoperative cerebrospinal fluid (CSF) leak is a significant complication of endoscopic endonasal approaches (EEA) to the skull base. The use of tissue sealants such as fibrin glue (Tisseel) or synthetic agents (PEI/PEG) is widespread in surgical practice, however, recent high-quality evidence challenges their clinical benefit and cost-effectiveness. This study aims to investigate whether the routine use of sealants in patient with peri-operatively assessed low CSF leak risk, significantly improves outcomes over no sealant use, to guide more cost- effective, evidence-based closure strategies. To the best of our knowledge, the present study is the first randomized clinical trial to evaluate the necessity and comparative effectiveness of fibrin and synthetic sealants versus no sealant in preventing postoperative CSF leaks following endoscopic endonasal surgery in low-post operative CSF leak risk patients.

Read the detailed description

Introduction Postoperative cerebrospinal fluid (CSF) leak is a significant complication of endoscopic endonasal approaches (EEA) to the skull base. The use of tissue sealants such as fibrin glue (Tisseel) or synthetic agents (PEI/PEG) is widespread in surgical practice, however, recent high-quality evidence challenges their clinical benefit and cost-effectiveness. This study aims to investigate whether the routine use of sealants in patient with peri-operatively assessed low CSF leak risk, significantly improves outcomes over no sealant use, to guide more cost- effective, evidence-based closure strategies. To the best of our knowledge, the present study is the first randomized clinical trial to evaluate the necessity and comparative effectiveness of fibrin and synthetic sealants versus no sealant in preventing postoperative CSF leaks following endoscopic endonasal surgery in low-post operative CSF leak risk patients. Materials and Methods This is a prospective, randomized, controlled, single-center clinical trial conducted at the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland.

Adult patients scheduled for endoscopic endonasal surgery (EES) will first undergo screening based on medical history and detailed radiological evaluation. Those who meet all predefined inclusion and exclusion criteria will be enrolled and randomized preoperatively using a computer-generated allocation sequence into one of three treatment arms: (1) no sealant (standard multilayer closure), (2) fibrin glue application (Tisseel®), or (3) synthetic polyethylene glycol-based sealant (Adherus®). Following randomization, surgery will be performed in accordance with the assigned intervention. The primary endpoint is the incidence of postoperative cerebrospinal fluid (CSF) leak within 3 months. Secondary outcomes include endoscopic evaluation of mucosal healing at 6 weeks and 3 months, postoperative complication rates (e.g., meningitis, pneumocephalus), reoperation rate, patient-reported quality of life, and a cost-effectiveness analysis comparing sealant use to standard closure. The study is designed and will be reported in accordance with the SPIRIT 2025 (Standard Protocol Items: Recommendations for Interventional Trials) guidelines to ensure methodological transparency and reproducibility. Results Initial enrollment includes a target of 225 patients (75 per arm). Interim data analysis focuses on early healing parameters, safety profiles, and cost metrics. Hypothesis testing will determine if either sealant significantly reduces CSF leak rates compared to no sealant and whether the marginal benefit justifies routine use in all patients. Exploratory endpoints include biomaterial handling characteristics and surgeon-reported usability. Conclusion The NoSeal Trial addresses a critical gap in evidence regarding the necessity and comparative performance of sealants in skull base reconstruction. By evaluating both clinical outcomes and economic impact, the study seeks to optimize surgical protocols and improve the safety and efficiency of endonasal neurosurgical procedures.

02

Conditions studied

  • CerebroSpinal Fluid (CSF) Leak

Browse trials for

Keywords

  • csf
  • pituitary adenoma
  • csf leak
  • sealant
03

In context

Pituitary Neoplasms

200 studies on the registry are indexed under Pituitary Neoplasms; 51 are open to participants now.

This study's planned enrollment of 225 is above the median of 60 across 121 interventional studies indexed under Pituitary Neoplasms.

Browse Pituitary Neoplasms studies →

Lead sponsor

Maria Sklodowska-Curie National Research Institute of Oncology is the lead sponsor of 64 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Scheduled for endoscopic endonasal surgery involving standard skull base reconstruction
  • Informed written consent obtained prior to enrollment
  • Hemodynamic and electrolyte stability before surgery
  • Procedure expected to be completed without use of high-flow intraoperative CSF diversion techniques

Exclusion criteria

Exclusion Criteria:

  • Revision surgery or extended endoscopic approaches requiring complex reconstruction (e.g., clival or cribriform defects)
  • Tumors requiring complex sella reconstruction from the start
  • Preoperative hydrocephalus
  • Known allergy to fibrin-based or synthetic sealant components
  • Active sinus infection or systemic inflammatory disease
  • Prior radiotherapy to the sellar or parasellar region
  • Uncontrolled diabetes mellitus ( > 7.0%)
  • Participation in another interventional trial that may influence wound healing or CSF assessment
  • Radiologic signs of chronic intracranial hypertension or hypotension
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
225 participants (estimated)

Study arms

  • Experimental
    No Sealant - Standard Multilayer Closure

    Patients in this arm will receive standard multilayer closure without the use of any sealant. Closure will involve mucosal flap repositioning and hemostatic agents (e.g., Surgicel®, TachoSil®), in accordance with standard endoscopic skull base reconstruction techniques.

    Procedure: Standard multilayer closure without sealant

  • Experimental
    Fibrin Glue - Tisseel® Application

    Patients will undergo standard multilayer closure followed by application of fibrin sealant (Tisseel®). This arm evaluates the effect of biologic tissue glue in preventing postoperative CSF leaks and promoting wound healing following endonasal skull base surgery.

    Device: Fibrin sealant application

  • Experimental
    Synthetic Sealant - Adherus® Application

    This arm involves standard multilayer closure followed by the application of a two-component synthetic polyethylene glycol-based sealant (Adherus®). The objective is to evaluate the synthetic agent's efficacy and cost-effectiveness in reducing postoperative CSF leaks.

    Device: Synthetic polyethylene glycol-based sealant

Interventions

  • ProcedureStandard multilayer closure without sealant

    Patients will undergo standard skull base reconstruction using mucosal flap repositioning and absorbable hemostatics (e.g., Surgicel®, TachoSil®), without application of any fibrin or synthetic sealant. This serves as the control group for comparison with sealant-assisted closures.

    Also known as: No-sealant technique, Control arm

  • DeviceFibrin sealant application

    Following standard multilayer closure, patients in this group will receive topical application of a fibrin-based biological sealant (Tisseel®). The intervention aims to assess its effectiveness in preventing postoperative cerebrospinal fluid (CSF) leak and promoting mucosal healing after endoscopic endonasal skull base surgery.

    Also known as: Tisseel®, Fibrin glue, Human fibrinogen/thrombin sealant

  • DeviceSynthetic polyethylene glycol-based sealant

    After standard multilayer closure, a synthetic two-component sealant (Adherus®, composed of polyethylene glycol and polyethylenimine) will be applied to reinforce the reconstruction site. This group is used to evaluate the efficacy and safety of synthetic sealant in preventing CSF leaks and supporting wound healing.

    Also known as: Adherus®, PEI/PEG sealant, Synthetic dural sealant

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative cerebrospinal fluid (CSF) leak within 90 days

    Postoperative CSF leak will be assessed clinically and endoscopically at multiple time points (Day 2, Day 30, Day 90). A leak will be defined as visible or symptomatic leakage of cerebrospinal fluid from the nasal cavity, confirmed by clinical exam and/or imaging when necessary. Assessment will be blinded and recorded using standardized diagnostic criteria.

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) to be shared will include: Demographics (age, sex) Preoperative imaging risk features Intraoperative findings (CSF leak grade, reconstruction technique) Treatment allocation (sealant type or no sealant) Primary and secondary outcomes (e.g., CSF leak occurrence, mucosal healing scores, complication rates, SNOT-22 and VAS scores) Follow-up data at 4 and 12 weeks Reoperation status Adverse events

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: De-identified individual participant data (IPD) and supporting documentation will be available beginning 6 months after publication of the primary results and will remain accessible for up to 36 months.

Access criteria: Access will be granted to qualified researchers affiliated with academic or non-commercial institutions who submit a methodologically sound research proposal. Access will include de-identified IPD and supporting documents (protocol, SAP, ICF, CSR, analytic code). Requests should be sent to the corresponding author. Data will be shared via secure institutional data-sharing platforms upon approval of the proposal and execution of a data use agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 46 interventional studies with no phase under Pituitary Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 68. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Oct 14, 2025
StartActual
Aug 15, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Mar 15, 2027
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07216157
Lead sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Responsible party
Wojciech Czyżewski (Wojciech Czyżewski MD, PhD, Neurosurgery Specialist, Principal Investigator, Maria Sklodowska-Curie National Research Institute of Oncology) — Principal investigator
First posted
Oct 14, 2025
Start date
Aug 15, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Oct 14, 2025

Study contacts

Wojciech Czyzewski, MD PhD, MD PhD
Contact
wojciech.w.czyzewski@gmail.com
+48788599550

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion